東阿阿膠(000423.SZ):聘任張名君為公司副總裁
格隆匯 11 月 20日丨東阿阿膠(000423.SZ)公佈,公司第九屆董事會第十八次會議決議,審議通過《關於聘任副總裁的議案》;
經公司總裁高登鋒提名,同意聘任張名君為公司副總裁,任期自本次董事會審議通過之日起至本屆董事會任期屆滿之日止。
張名君,男,1979年1月生,持有北京航空航天大學管理學、法學雙學士學位和中國人民大學工商管理碩士學位。曾任華潤醫藥控股有限公司北京產業園事業部行政綜合與6S管理高級經理,華潤醫藥產業發展(北京)有限公司行政綜合與6S管理高級經理,華潤醫藥集團有限公司辦公室高級經理、辦公室副總經理、黨委辦公室副主任、紀檢監察部副總經理等職務。現任東阿阿膠股份有限公司黨委委員、紀委書記。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.